Replies to post #59218 on Biotech Values

[DewDiligence]

MNTA’s M118: FIIa vs FXa Binding
This graphic shows why LMWH has less
inhibition of thrombin (FIIa) than of FXa.



LMWH is a complex mixture of variable-length
chains, of which some are capable of binding to
FIIa and some aren’t. Relative to unfractionated
heparin, fewer chains in LMWH are capable of
binding to FIIa and thus LMWH provides
anticoagulation mainly by inhibiting FXa.

M118 from MNTA is a proprietary mixture of
short- and long-chain heparins that is designed
from the ground up to have the binding qualities
and reversibility of unfractionated heparin while
retaining the predictability of response and lack
of monitoring that are the hallmarks of LMWH.

This graphic is best viewed in conjunction with
#msg-26897966, which shows the clotting cascade.

Source of graphic:
http://www.cardiologyrounds.org/crus/crus-12-97.pdf

[croumagnon]

Re: The Clotting Cascade

Even this simplified version seems quite complicated for many of us. For instance, I always thought that Prothrombin times were viewed as the main indicators for clotting efficiency but clearly your diagram shows that things are a lot more complicated than that...

It would be helpful for some of us who are not well versed in this field if you could identify the places where the various agents work in this cascade, such as Plavix (if it can have a role in this cascade whatsoever), Aspirin, ATryn, Coumadin, and heparin...

TIA